Objective: Retrospective study on the safety and efficacy of anlotinib in the treatment of advanced leiomyosarcoma in real-world.
Methods: Clinical data were collected from patients suffered from advanced leiomyosarcoma who received anlotinib treatment in Cancer Hospital of the University of Chinese Academy of Sciences from January 2018 to December 2020. Objective response rate (ORR) and disease control rate (DCR) were analyzed according to the RECIST 1.1 criteria. The progression free survival (PFS), overall survival (OS) and adverse reactions were recorded and calculated.
Results: A total of 19 patients (14 female, 5 male) were enrolled, 3 (15.8%) achieved partial response (PR), 11 (57.9%) achieved stable disease (SD), with an ORR of 15.8%, a DCR of 73.7%, a median PFS of 4.1 months (95% CI: 3.0~5.2) and a median OS of 23.5 months (95% CI: 14.2~32.7). The majority of adverse events were grade 1/2, the most common grade 3/4 adverse events were hand-foot syndrome (12.5%), hypertension (5.3%) and oral ulcer (5.3%).
Conclusion: Our results forecast that anlotinib is effective, safe and alternative in treatment of advanced leiomyosarcoma in real-world, combined with immunotherapy may become a potential treatment option. Further, more prospective randomized controlled trials are needed to confirm these findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109731 | PMC |
| http://dx.doi.org/10.2147/CMAR.S357334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TRPV4 drives the progression of leiomyosarcoma by promoting ECM1 generation and co-activating the FAK/PI3K/AKT/GSK3β pathway.
Cell Oncol (Dordr)
November 2024
Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Purpose: Leiomyosarcoma (LMS) is an aggressive mesenchymal malignant tumor with poor therapeutic options, but the molecular mechanisms underlying LMS remain largely unknown. Increasing evidence indicates that transient receptor potential vanilloid 4 (TRPV4) levels are closely related to the advancement of various malignant tumors through diverse molecular mechanisms. However, the roles and regulatory mechanisms of TRPV4 in LMS progression remain unclear.
View Article and Find Full Text PDFPazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry.
ESMO Open
December 2024
Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: Pazopanib is part of the therapeutic armamentarium for the treatment of patients with advanced non-adipocytic soft tissue sarcomas (STS) who have received prior chemotherapy, but its optimal use in STS histologies is still left to be further defined.
Design And Methods: Data on STS patients treated with pazopanib in Italy have been prospectively collected from July 2013 to December 2019 through a drug monitoring registry managed by the Italian Medicines Agency (AIFA). This nationwide observational cohort study included patients with advanced STS who received pazopanib.
Pancreatic Leiomyosarcoma With Multi-organ Metastases: A Rare Case.
Cureus
October 2024
Oncology/Radiation Oncology, Tawam Hospital, Al Ain, ARE.
This case report describes the diagnosis, treatment, and progression of a 50-year-old male patient diagnosed with stage IV pancreatic leiomyosarcoma with metastases to the liver, lungs, and brain, representing the only case involving both the pancreas and brain documented in the hospital registry with a histopathological diagnosis of leiomyosarcoma. The patient initially presented with chronic abdominal pain, constipation, and weight loss, and subsequent CT scans revealed a large pancreatic mass with metastases to the liver, lungs, and brain. A biopsy confirmed the diagnosis of leiomyosarcoma, and the patient underwent eight cycles of palliative chemotherapy with cisplatin and docetaxel, along with palliative radiotherapy targeting the brain metastases.
View Article and Find Full Text PDFHigh circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy.
Oncoimmunology
December 2024
Equipe labellisée par La Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.
View Article and Find Full Text PDFThe diagnostic value of endoscopic ultrasound for esophageal subepithelial lesions: A review.
Medicine (Baltimore)
November 2024
Department of Thoracic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Article Synopsis
- Esophageal subepithelial lesions (ESELs) include a range of tumors and diseases, such as leiomyomas and hemangiomas, often going undetected due to asymptomatic presentations.
- Common imaging methods for ESEL diagnosis involve conventional endoscopy, spiral computed tomography, and endoscopic ultrasound (EUS), with EUS being the most accurate.
- Recent advancements in EUS technology, including artificial intelligence and enhanced imaging techniques, have improved diagnostic accuracy for ESELs and helped reduce missed cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!